Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995556 | 1.00 | HTRA1 (0.44) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL19995593 | 1.00 | HTRA1 (0.44) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL19995596 | 1.00 | HTRA1 (0.44) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL2379316 | 0.87 | HTRA1 (0.49) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29035325 | 0.87 | HTRA1 (0.49) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL25365634 | 0.87 | HTRA1 (0.49) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1827825 | 0.87 | HTRA1 (0.49) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL24645319 | 0.87 | HTRA1 (0.49) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL23454767 | 0.84 | CYP1A2 (0.38) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL21527811 | 0.84 | CYP1A2 (0.38) | HTRA1CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715633-B | Dopamine-beta-hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | BIAL—Portela & Cᵃ, S.A. (PT) | 2021-06-15 | — | — | US | disclosed |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | BIAL—Portela & Cᵃ, S.A. (PT) | 2021-06-15 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2020-06-11 | — | — | US | disclosed |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2020-06-11 | — | — | US | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| EP-3515433-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| EP-3515917-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018056855-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018056855-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | HTRA1 598/4885CYP1A2 147/4885POLB 678/4885 |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | HTRA1 689/4885CYP1A2 136/4885POLB 633/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | HTRA1 660/4885CYP1A2 145/4885POLB 710/4885 |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, SLC6A3 | HTRA1 1316/4885CYP1A2 146/4885POLB 620/4885 |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, COMT | HTRA1 1221/4885CYP1A2 174/4885POLB 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.